CSIMarket
 


Eli Lilly And Company  (LLY)
Other Ticker:  
 


Eli Lilly's ROA from the fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Eli Lilly's ROA in the fourth quarter of 2023?
Eli Lilly And Company achieved a return on average assets (ROA) of 9.12 % in its fourth quarter of 2023, which is below Eli Lilly's average return on assets, which stands at 10.28%.

ROA fell compared to the third quarter of 2023, despite the net income growth of % from the third quarter of 2023.

However, within the Healthcare sector 53 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2023 quarter, so far to 516, from total ROA ranking in the third quarter of 2023 at 646.

What is ROA?


Return On Assets (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Total Assets Change 29.33 % 22.02 % 16.47 % 13.31 % 1.4 %
Y / Y Net Income Change 13.01 % - 85.11 % -29.32 % 12.26 %
Net Income (TTM) in million 5,240 4,988 6,498 5,687 6,245
Return On Assets (TTM) 9.12 % 9.26 % 12.68 % 11.54 % 13.08 %
LLY's Total Ranking # 516 # 646 # 474 # 576 # 580
Total Assets (TTM) in million 64,008 57,917 54,817 53,164 49,491
Seq. Total Assets Change 10.52 % 5.66 % 3.11 % 7.42 % 4.27 %
Seq. Net Income Change - - 31.1 % -30.59 % 33.48 %



Return On Assets Company Ranking
Within: No.
Industry # 17
Sector # 54
Overall # 514

Return On Assets Statistics
High Average Low
21.63 %
10.28 %
-7.41 %
(Dec 31 2019)   (Dec. 31, 2008)





Financial Statements
Eli Lilly's Assets $ 64,008 million LLY's Balance sheet
Eli Lilly's Income $ 2,190 million Quarterly LLY's Income Statement
LLY's Income by Division See LLY's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023
(Dec 31 2022)
FY 2022
(Dec 31 2021)
FY 2021
(Dec 31 2020)
FY 2020
(Dec 31 2019)
FY 2019
Y / Y Total Assets Change 29.33 % 1.4 % 4.66 % 18.7 % -10.53 %
Total Assets in million 64,008 49,491 48,806 46,633 39,286
Y / Y Net Income Change -16.08 % 11.88 % -9.88 % -25.54 % 157.38 %
Net Income in million 5,240 6,245 5,582 6,194 8,318
Return On Assets 8.19 % 12.62 % 11.44 % 13.28 % 21.17 %




Comment on LLY's ROA in the fiscal year ending 2023
In the fiscal year 2023 Eli Lilly's ROA decreased compared to previous year to 8.19 %, due to deterioration of net income -16.08 % to $5,240.40 million, from $6,244.80 million a year ago, as LLY's assets were $64,008.10 million.


More Return On Assets Ratios
LLY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LLY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Roa for LLY's Competitors
Roa for Eli Lilly's Suppliers
Return On Assets for LLY's Customers

You may also want to know
LLY's Roi LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Comparisons
LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2023, within Healthcare Sector ROA
National Research Corporation  24.27 %
Mettler toledo International Inc   23.50 %
Inmode Ltd   22.93 %
Lantheus Holdings Inc   22.30 %
Johnson and Johnson  19.49 %
Medpace Holdings Inc   19.02 %
Earth Science Tech Inc   18.41 %
Corcept Therapeutics Inc  17.90 %
Chemed Corporation  17.68 %
Cardiff Lexington Corporation  17.40 %
Vertex Pharmaceuticals Inc  17.28 %
Harmony Biosciences Holdings inc   16.82 %
Zoetis Inc   16.75 %
Catalyst Pharmaceuticals Inc   16.47 %
West Pharmaceutical Services Inc   15.85 %
Halozyme Therapeutics Inc   15.78 %
Edwards Lifesciences Corporation  15.38 %
Exelixis Inc   15.25 %
Novartis Ag  14.86 %
Alpha Pro Tech Ltd   14.69 %
United Therapeutics Corporation  14.47 %
Resmed Inc   13.14 %
Utah Medical Products Inc  13.07 %
Shockwave Medical Inc   12.78 %
Intuitive Surgical Inc   12.73 %
Regeneron Pharmaceuticals Inc   12.56 %
Orasure Technologies Inc  11.57 %
Ufp Technologies Inc   11.28 %
Royalty Pharma Plc  10.24 %
Protalix Biotherapeutics inc   10.17 %


Date modified: 2024-02-21T21:05:59+00:00


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com